1-4 of 4
James M. Reuben
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract C22: A phase Ib study of the CXCR1/2 inhibitor Reparixin in combination with weekly paclitaxel in metastatic HER2 negative breast cancer - final analysis

Anne F. Schott, Max S. Wicha, Raymond P. Perez, Giraldo Kato, Tiffany Avery, Massimo Cristofanilli, James M. Reuben, R. Katherine Alpaugh, Pier Adelchi Ruffini, Susan Mccanna, Lori J. Goldstein
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C22.
https://doi.org/10.1158/1535-7163.TARG-15-C22
Published: 01 December 2015
View article titled, Abstract C22: A phase Ib study of the CXCR1/2 inhibitor Reparixin in combination with weekly paclitaxel in metastatic HER2 negative breast cancer - final analysis
Journal Articles

Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma

Vianey Gonzalez-Villasana, Cristian Rodriguez-Aguayo, Thiruvengadam Arumugam, Zobeida Cruz-Monserrate, Enrique Fuentes-Mattei, Defeng Deng, Rosa F. Hwang, Huamin Wang, Cristina Ivan, Raul Joshua Garza, Evan Cohen, Hui Gao, Guillermo N. Armaiz-Pena, Paloma del C. Monroig-Bosque, Bincy Philip, Mohammed H. Rashed, Burcu Aslan, Mumin Alper Erdogan, Yolanda Gutierrez-Puente, Bulent Ozpolat, James M. Reuben, Anil K. Sood, Craig Logsdon, Gabriel Lopez-Berestein
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (11): 2583–2594.
https://doi.org/10.1158/1535-7163.MCT-14-0028
Published: 03 November 2014
View article titled, Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma
Open the PDF for Bisphosphonates Inhibit Stellate Cell Activity and Enhance Antitumor Effects of Nanoparticle Albumin–Bound Paclitaxel in Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract B51: ApoStream™ isolated circulating tumor cells from primary breast cancer patients reveals heterogeneous phenotypes related to epithelial-mesenchymal transition and stem cell markers.

Kenna L. Anderes, Insiya Jafferji, Vladislava O. Melnikova, Jackson A. Summer, Darren W. Davis, James M. Reuben, Naoto T. Ueno
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B51.
https://doi.org/10.1158/1535-7163.TARG-13-B51
Published: 01 November 2013
View article titled, Abstract B51: ApoStream™ isolated circulating tumor cells from primary breast cancer patients reveals heterogeneous phenotypes related to epithelial-mesenchymal transition and stem cell markers.
Journal Articles

Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer

Antonio Giordano, Hui Gao, Simone Anfossi, Evan Cohen, Michal Mego, Bang-Ning Lee, Sanda Tin, Michele De Laurentiis, Charla A. Parker, Ricardo H. Alvarez, Vicente Valero, Naoto T. Ueno, Sabino De Placido, Sendurai A. Mani, Francisco J. Esteva, Massimo Cristofanilli, James M. Reuben
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (11): 2526–2534.
https://doi.org/10.1158/1535-7163.MCT-12-0460
Published: 08 November 2012
View article titled, Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer
Open the PDF for Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer in another window
Includes: Supplementary data